Archived: 6th Winter Conference
on Medicinal & Bioorganic Chemistry
January 23rd - 28th 2005
Steamboat Springs Resort, Colorado
Agenda
Sunday, January 23rd 2005
Organic Synthesis in Non-classical Media
Program Chair: Michael Van Nieuwenhze, University of California
Organic Synthesis in Water and Other Polar Media: An Overview
‘In Situ’ Click Chemistry: Enzyme Inhibitors Made to Their Own Specifications
Lewis Acid Catalysis in Aqueous Media
Monday, January 24th 2005
General Oral Session
Program Chair: Bryan Norman, Eli Lilly & Company
Blockbuster Drug Symposium
Program Chair: Lester Mitscher, University of Kansas
The Viagra Story
The Kaletra-Ritonavir Story
The Neurontin Story
Cascade Chemistry
Program Chair: Victor Snieckus, Queen’s University
Reagents in Organic Synthesis: The Discovery and the Early Years
Transition Metal Catalyzed Sequential Coupling via C-H Bond Cleavage
Concepts of Nature in Organic Synthesis: Cascade Catalysis and Multistep Conversions in Concert
Tandem and Cascade Carbon-Carbon Bond-Forming Processes Catalyzed by Pd and Zr Complexes
Tuesday, January 25th 2005
Solid-supported Reagents
Program Chair: Tony Barrett, Imperial College
Soluble Polymers as Easily Separable Supports in Synthesis and Catalysis
ROM-Polymerization Strategies for Facilitated Synthesis
Development of New Methods for Organic Synthesis
Polymer-Assisted Solution-Phase (PASP) Chemical Library Synthesis and its Application on the Tissue Factor VIIa Projects
Wednesday, January 26th 2005
General Oral Papers I
Program Chair: Dennis Dean, Merck Research Labs
Benzopyrans are selective ERbagonists for use in the treatment of prostatic diseases
Design and Development of Low Toxicity UAB-rexinoids for Breast Cancer Chemoprevention
In vitro and In vivo of a ketone-containing avb3 integrin antagonist for the treatment for osteoporosis
Computational and Pharmacokinetic Studies Directed at Understanding the Differences in Oral Bioavailability Seen between Closely Related aVb3integrin Antagonists
Synthesis of Immunomodulatory Macrolides for Cystic Fibrosis
Progression of a Novel Class of Orally Active p38 Map Kinase Inhibitors
Synthesis and Modelling Studies of Peptidomimetic Aldehydes Related to a Cataract Preventing Calpain Inhibitor
Structure-based design of a series of potent and selective cell permeable inhibitors of humanb–secretase
Chemistry Quality and the Medicinal Chemistry- Biology Interface
Program Chair: Chris Lipinski, Pfizer Global Research & Development
Thursday, January 27th 2005
Protein Conformational Plasticity in Drug Design
Program Chair: Dan Flynn, Deciphera Pharmaceuticals
Drug Discovery at Adaptive Signaling Interfaces
Dallas Binding Sites and Conformational Changes in Protein Kinases
Exploiting Plasticity in Nuclear Receptor Drug Discovery
Small Molecule Modulation of Protein-Protein Interactions
Program Chair: Peter Toogood, Pfizer
Targeting Protein-Protein and Protein-DNA Interaction using Solution Phase Combinatorial Chemistry
The Poisoning of Human Topoisomerase I by Structurally Diverse Anticancer Compounds and Various Insults to DNA
Challenges for Drug Discovery at Protein/Protein Interfaces
Starting Small and Strong: Fragment Based Drug Discovery
Friday, January 28th 2005
General Oral Papers II
Program Chair: Philippe Nantermet, Merck Research Laboratories
Development of a Potent HIV-1 Integrase Inhibitor with a Unique Resistance Profile
Double Oxidation of Tryptophanes: Synthesis of the Potent Anthelmintic Pyrrolobenzoxazine CJ-126621
Calcitonin gene-related peptide antagonists
APD 356, A Potent and Selective 5HT2C Agonist is a Potential New Treatment for Obesity
Diagnostics Structure-based Optimization of Novel Azepane Derivatives as PKB Selective Inhibitors
Identification and Development of Potent and Selective P13Kỷ Inhibitors
Unusual Heterocycle Synthesis: Routes to Pyrazolo[1,5-a]Pyridine Compounds as P38 Kinase Inhibitors